Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Hepatitis

  Free Subscription


15.03.2021

1 AIDS
1 Clin Infect Dis
1 Hepatology
1 Int J Cancer
2 J Hepatol
2 J Med Virol
3 PLoS One
1 Vaccine
1 Z Gastroenterol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AIDS

  1. FRENCH AL, Grennan D, Daubert E, Seaberg EC, et al
    Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women.
    AIDS. 2021 Mar 11. pii: 00002030-900000000-96468.
    PubMed         Abstract available


    Clin Infect Dis

  2. CASSEB J, Marcusso RMN, Monteiro M, Assone T, et al
    Human T-Cell Lymphotropic Virus/Human Immunodeficiency Virus, and Hepatitis C Virus Coinfection: Clinical Outcomes After 22 Years of Follow-up in Sao Paulo City.
    Clin Infect Dis. 2021 Mar 2. pii: 6156779. doi: 10.1093/cid/ciaa1008.
    PubMed        


    Hepatology

  3. GANE EJ, Kim HJ, Visvanathan K, Kim YJ, et al
    Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B.
    Hepatology. 2021 Mar 11. doi: 10.1002/hep.31795.
    PubMed         Abstract available


    Int J Cancer

  4. PETRICK JL, Florio AA, Znaor A, Ruggieri D, et al
    International trends in hepatocellular carcinoma incidence, 1978-2012.
    Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32723.
    PubMed         Abstract available


    J Hepatol

  5. LEE HA, Kim BK, Kim SU
    Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy.
    J Hepatol. 2020 Apr 1. pii: S0168-8278(20)30121.
    PubMed        

  6. PAPATHEODORIDIS GV, Lampertico P
    Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy".
    J Hepatol. 2020 Mar 27. pii: S0168-8278(20)30173.
    PubMed        


    J Med Virol

  7. YANG J, Xiong Y, Zhou L, Huang Y, et al
    Soluble E-cadherin is associated with oxidative stress in patients with chronic HBV infection.
    J Med Virol. 2020;92:34-44.
    PubMed         Abstract available

  8. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    PubMed         Abstract available


    PLoS One

  9. RAJHI M, Haddad-Boubaker S, Chouikha A, Bourquain D, et al
    Identification of two novel hepatitis C virus subtype 2 from Tunisia (2v and 2w).
    PLoS One. 2021;16:e0248249.
    PubMed         Abstract available

  10. DAN-NWAFOR CC, Adeoye I, Aderemi K, Onuoha M, et al
    Serological markers and risk factors associated with Hepatitis B virus infection among Federal Capital Territory prison inmates, Nigeria: Should we be concerned?
    PLoS One. 2021;16:e0248045.
    PubMed         Abstract available

  11. MCINTOSH AT, Wei R, Ahn J, Aouizerat BE, et al
    A genomic variant of ALPK2 is associated with increased liver fibrosis risk in HIV/HCV coinfected women.
    PLoS One. 2021;16:e0247277.
    PubMed         Abstract available


    Vaccine

  12. ACCROMBESSI M, Adetola CV, Bacharou S, Dossou Y, et al
    Assessment of the anti-HBs antibody response in Beninese infants following 4 doses of HBV vaccine, including administration at birth, compared to the standard 3 doses regime; a cross-sectional survey.
    Vaccine. 2019 Dec 19. pii: S0264-410X(19)31673.
    PubMed         Abstract available


    Z Gastroenterol

  13. SIMON KG, Serfert Y, Buggisch P, Mauss S, et al
    [Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries].
    Z Gastroenterol. 2021;59:241-249.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: